

SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.


Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
Reprieve’s press office: +44 (0) 207 553 8161
The hearing will discuss what remedies the government owes two families, victims of an MI6-CIA rendition operation, if the government spied on legally privileged communications between them and their lawyers.
Abdul Hakim-Belhaj and his wife Fatima Boudchar were kidnapped, tortured and sent to Libya in 2004 in a joint MI6-CIA operation. A second rendition operation targeted Sami al-Saadi, his wife Karima Ait Baaziz, and their four children between the ages of six and twelve. Both families filed a case in 2013 with the IPT concerning alleged eavesdropping by UK intelligence services on their confidential communications with their lawyers.
In 2012, the Belhaj family had brought a separate, civil case against the UK Government over the part it played in their mistreatment. (The al-Saadis had filed a similar claim, which subsequently settled; both families are witnesses in an ongoing Scotland Yard investigation into the kidnappings.)
The IPT case centres around whether Government lawyers and officials involved in the torture case, through surveillance of the families' communications with their lawyers at Reprieve and Leigh Day, accessed confidential communications about their legal cases, thereby giving the Government an unfair advantage in court.
Cori Crider, Reprieve Strategic Director and attorney for Mr Belhaj, said: "If the government has spied on these families' private calls with their lawyers, we must know about it, and take steps to restore the families' right to a fair trial. The government has admitted it ran unlawful policies on lawyer-client spying for years, including for the entire period our case was being prepared. This raises a number of stark questions: how much of our privileged material was collected? Who saw it? For how long were the involved in the torture claims? What of the police investigation - has that, too, been compromised? The government must be made to address these issues if confidence in the justice system is to be maintained."
Reprieve is a UK-based human rights organization that uses the law to enforce the human rights of prisoners, from death row to Guantanamo Bay.
One senior DHS official said the program "is just the first step in breaching people’s privacy settings in ways that they are not even aware of.”
US Department of Homeland Security agents are increasingly infiltrating social media platforms to monitor users, collect intelligence, and target people, according to new reporting based on leaked documents.
Ken Klippenstein exposed the open source monitoring program, which DHS calls "masked engagement," with new reporting Thursday that details how agents "assume false identities and interact with users—friending them, joining closed groups, and gaining access to otherwise private postings, photographs, friend lists, and more."
"A senior [DHS] official tells me that over 6,500 field agents and intelligence operatives can use the new tool, a significant increase explicitly linked to more intense monitoring of American citizens," Klippenstein wrote.
The so-called "masked engagement" by DHS operatives online comes as actual masked federal agents are engaged in the Trump administration's deadly deployments in communities nationwide.
Important to note that "Authorized" here means that DHS/ICE have given *Themselves* permission to do this "masked engagement" bullshit, not that either congress or the courts say it's okay.Challenge this everywhere & every way possible, & in the meantime, keep ourselves & each other safe as we can
[image or embed]
— Dr. Damien P. Williams can't think of a fun display name right n (@wolvendamien.bsky.social) February 12, 2026 at 4:46 PM
Masked engagement adds a new level to DHS' open source intelligence (OSINT) collection regime, which previously consisted of overt engagement, overt research, overt monitoring, masked monitoring, and undercover engagement. Masked engagement, in which agents conceal their government affiliation without assuming a false identity while interacting with a target, is a step below undercover engagement, in which DHS operatives use false identities and cover stories.
According to Klippenstein:
Masked monitoring allows officers at agencies like [Immigration and Customs Enforcement] and Border Patrol to use alias accounts to passively observe public online activity. Crucially, this level of monitoring bars DHS representatives from interacting with other users directly. Under masked monitoring, officers are not allowed to ask an admin for entry into a private group or to “friend” a target to see non-public posts.
But with masked engagement (separate from masked monitoring), that firewall has now been dismantled. The only restriction imposed on masked engagement is that DHS officers [note] the threshold of “substantive engagement”—a term the rules leave conveniently ill-defined.
"By labeling this a 'middle ground' between monitoring and full-blown undercover work, the DHS allows agents to infiltrate private digital spaces without the rigorous internal approvals and legal checks required for a formal undercover 'sting,'" Klippenstein explained.
Sources told Klippenstein that DHS has been using masked engagement tactics to infiltrate pro-Palestine groups in the United States and to compile databases of suspected Mexican and Mexican American transnational criminals.
“Open source monitoring has become so ubiquitous that we even have databases of identities used by the department to track our own online engagements,” the senior DHS official said.
“Yes, we have safeguards against violating people’s privacy, but masked engagement is just the first step in breaching people’s privacy settings in ways that they are not even aware of," they added.
Rachel Levinson-Waldman, director of the Brennan Center for Justice's Liberty and National Security Program, told Klippenstein that “CBP’s expansion into what they’re calling ‘masked engagement’ is cause for real concern."
“This new capability is being shoehorned in one step below undercover engagement (which already allows for a lot of overreach), it appears CBP believes that friending someone, following them, or joining a group is not as invasive as directly engaging or interacting with individuals," she continued.
“In addition, doing so through an alias account—an account that doesn’t reveal the user’s CBP affiliation, and pretends to be someone else—will weaken trust in government and weaken the trust that is critical to building community both online and off,” Levinson-Waldman added.
A DHS spokesperson told Klippenstein that the agency "has utilized its congressionally directed undercover authorities to root out child molesters and predators for years."
“We will continue using every tool at our disposal to protect the American people as our agents and officers Make America Safe Again," they added.
Those tools include an error-plagued mobile facial recognition application, mass phone surveillance technology, data broker platforms that allow operatives to circumvent warrant requirements, forensic extraction to bypass phone locks, artificial intelligence and predictive analytics, and more.
Civil liberties groups, digital rights advocates, and some Democratic lawmakers are pushing back.
Last week, Sens. Ed Markey (D-Mass.), Jeff Merkley (D-Ore.), Ron Wyden (D-Ore.), and Rep. Pramila Jayapal (D-Wash.) introduced the ICE Out of Our Faces Act, legislation that would ban ICE and Customs and Border Protection "from acquiring and using facial recognition technology and other biometric identification systems."
The bill would "also require the deletion of all data collected for use in or by biometric identification systems and allow individuals and state attorneys general to seek civil penalties for violations."
"President Trump has given up on caring about protecting working class Americans and has given the keys to our economy to billionaire scammers."
Alarms are being raised amid reports that President Donald Trump is stacking a key regulatory committee with CEOs of online prediction markets, cryptocurrency firms, and sports betting apps.
As reported on Thursday by the right-wing Daily Wire, the Commodity Futures Trading Commission (CFTC) is launching a new initiative called the Innovation Advisory Committee, which CFTC Chairman Michael Selig said would be tasked with ensuring "the CFTC’s decisions reflect market realities so the agency can future-proof its markets and develop clear rules of the road for the Golden Age of American Financial Markets."
Among the members of the committee are Tarek Mansour, CEO of online betting market Kalshi; Brian Armstrong, CEO of cryptocurrency hub Coinbase; Christian Genetski, president of the FanDuel sports betting app; and Matt Kalish, president of sports betting app DraftKings North America.
Emily Peterson-Cassin, education fund policy director at Demand Progress, said the committee's composition has deeply concerning implications for the future of the US economy.
"The corruption couldn’t be more obvious," said Peterson-Cassin. "It’s hard to see the CTFC succeeding at its mission to prevent a repeat of the 2008 financial crisis when it is influenced from the inside by a rogues’ gallery of billionaire CEOs responsible for monetizing and gamifying virtually every aspect of everyday life."
Peterson-Cassin added that the latest move shows that "President Trump has given up on caring about protecting working class Americans and has given the keys to our economy to billionaire scammers.”
The creation of the Innovation Advisory Committee wasn't the only news made by CFTC this week, as Barron's reported on Monday that the commission's enforcement division based in Chicago has now been completely gutted, as its entire litigation team has either resigned or been laid off.
One laid-off former CFTC attorney told Barron's that the gutting of the office will make it much easier for financial scammers to rip off Americans.
"If I was a different person I would launch a crypto scam right now," said the attorney, "because there’s no cops on the beat."
"The president should work with Democrats and Republicans to actually lower prescription drug costs for families," said Sen. Maggie Hassan, "rather than helping Big Pharma line its pockets."
Democratic members of the congressional Joint Economic Committee on Friday released a report warning that US families could end up spending thousands of dollars more on prescription drugs because of a website recently unveiled by President Donald Trump.
Launched last week with pharmaceutical companies, TrumpRx.gov is marketed as an aggregator to help patients save on prescription drugs by using manufacturer coupons or buying directly from manufacturers.
However, as the new report highlights, "many of the brand-name drugs listed on TrumpRx have significantly cheaper generic alternatives, which are excluded from TrumpRx. This means that TrumpRx steers families to pay more to Big Pharma when they could be getting the same medication at a much lower price."
"No matter what the president says, the bottom line is that TrumpRx directs families to buy expensive brand-name drugs when generic versions are available elsewhere at a fraction of the cost."
The report provides a chart comparing TrumpRx and generic prices, both for one prescription fill and the full annual cost. It also notes the difference. In some cases, the president's option is $10-50 more a year. However, there are also examples in which families could save hundreds or thousands of dollars with generic drugs.
For example, Colestid, a medication that lowers cholesterol, would cost $2,771.21 a year through TrumpRx, compared with $856.70 for the generic option, a difference of $1,914.51. The antidepressant Pristiq is $2,401.20 on the president's website, versus just $320.88 for the generic, a potential yearly savings of $2,080.32.
The biggest difference featured in the document is for Tikosyn, which helps patients maintain a normal heart rhythm. The TrumpRx annual cost is $4,032, whereas the generic is only $192.68, a difference of $3,839.32.
The report also stresses how extra costs from the president's site could stack up for households in which multiple people need medication:
"No matter what the president says, the bottom line is that TrumpRx directs families to buy expensive brand-name drugs when generic versions are available elsewhere at a fraction of the cost," said Sen. Maggie Hassan (D-NH), ranking member of the Joint Economic Committee and the Senate Finance Subcommittee on Health Care.
"The president should work with Democrats and Republicans to actually lower prescription drug costs for families," Hassan argued, "rather than helping Big Pharma line its pockets."
While the Trump White House responded defensively to the Democratic report, with spokesperson Kush Desai claiming to MS NOW that "product listings on TrumpRx.gov are in no way an endorsement for use of any prescription drug over another" and accusing Democrats of "resorting to idiotic or simply ignorant lines of attack instead of simply giving the president credit where it's due," the panel members aren't alone is highlighting such cost differences.
The added cost for US families also isn't lawmakers' only concern about TrumpRx. Last month, shortly before the site's launch, Democratic Sens. Dick Durbin (Ill.) Elizabeth Warren (Mass.), and Peter Welch (Vt.) sent a letter to the US Department of Health and Human Services Office of Inspector General raising concerns about the new direct-to-consumer (DTC) platform.
"There appear to be possible conflicts of interest involved in the potential relationship between TrumpRx and an online dispensing company, BlinkRx, on whose board the president's son, Donald Trump Jr., has sat since February 2025," they wrote. "Moreover, legitimate concerns about inappropriate prescribing, conflicts of interest, and inadequate care have been raised about the exact types of DTC platforms to which TrumpRx would route patients."
The trio also expressed alarm about high prices, noting that "pharmaceutical manufacturers who will reportedly be participating in TrumpRx have spent billions of dollars in combined advertising expenses for drugs sold on existing DTC platforms."
"The pharmaceutical industry's outrageous DTC advertisements fuel demand for specific medications, which balloon healthcare expenses," the senators wrote. "We are concerned that DTC advertising, including in relation to TrumpRx, will steer customers to prescriptions that may be reimbursed by federal health programs, creating the potential for unnecessary or wasteful spending."